These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38224028)

  • 1. Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.
    Sadat Larijani M; Biglari A; Sorouri R; Salehi-Vaziri M; Doroud D; Azadmanesh K; Fotouhi F; Mostafavi E; Ramezani A
    Iran Biomed J; 2024 Jan; 28(1):1-7. PubMed ID: 38224028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
    Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M
    Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines against SARS-CoV-2 variants and future pandemics.
    Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
    Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological surveillance of respiratory viral infections in SARS-CoV-2-negative samples during COVID-19 pandemic in Iran.
    Maleki A; Mehrbod P; Bokharaei-Salim F; Eybpoosh S; Tavakoli M; Mohammadnejad AE; Hosseini Z; Kashanian S; Asadi LF; Salehi-Vaziri M; Fotouhi F
    Virol J; 2023 Dec; 20(1):296. PubMed ID: 38093303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges of COVID-19 Vaccination in Iran: In the Fourth Wave of Pandemic Spread.
    Heidari M; Jafari H
    Prehosp Disaster Med; 2021 Oct; 36(5):659-660. PubMed ID: 34287113
    [No Abstract]   [Full Text] [Related]  

  • 11. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
    Shih HI; Wu CJ; Tu YF; Chi CY
    Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of COVID-19 vaccine from laboratory to clinic.
    Saravanan V; Chagaleti BK; Narayanan PL; Anandan VB; Manoharan H; Anjana GV; Peraman R; Namasivayam SKR; Kavisri M; Arockiaraj J; Muthu Kumaradoss K; Moovendhan M
    Chem Biol Drug Des; 2024 Jan; 103(1):e14383. PubMed ID: 37953736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Laboratory in Emerging Infectious Disease Control in Iran, Pasteur Institute of Iran, and national laboratory network.
    Maleki A; Mostafavi E; Fazlalipour M; Salehi-Vaziri M
    Influenza Other Respir Viruses; 2023 Dec; 17(12):e13232. PubMed ID: 38090228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Vaccines: Where Did We Stand at the End of 2023?
    Lundstrom K
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minding the "T"s beyond the "B"s: Shaping vaccines for future pandemics.
    Kalimuddin S; Ooi EE
    PLoS Biol; 2023 Nov; 21(11):e3002351. PubMed ID: 37934720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
    Ma C; Su S; Wang J; Wei L; Du L; Jiang S
    Microbes Infect; 2020; 22(6-7):245-253. PubMed ID: 32437926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.
    Mirtaleb MS; Falak R; Heshmatnia J; Bakhshandeh B; Taheri RA; Soleimanjahi H; Zolfaghari Emameh R
    Int Immunopharmacol; 2023 Apr; 117():109934. PubMed ID: 36867924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.